SSS. A. Sukhanov

S. A. Sukhanov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


S. A. Sukhanov has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical observation of a patient with chronic COVID-19 and type 2 diabetes mellitus

    by S. A. Sukhanov, O. V. Zanozina, Yu. A. Sorokina, V. N. Lagonskaya, M. V. Kobalava, С. А. Суханов, О. В. Занозина, Ю. А. Сорокина, В. Н. Лагонская, М. В. Кобалава

    This article describes the clinical observation of the patient who developed multiple new diseases after suffering a new coronavirus infection in 2020. Before COVID-19, she had only been diagnosed with hypertension. The patient experienced a severe case of COVID-19, developing pneumonia (CT2) in 2020 (at age 52), Four months later, diabetes mellitus was newly diagnosed, and three months later bronchial asthma and paroxysmal arrhythmias were diagnosed . Three years later, in 2024, the patient again experienced a new coronavirus infection, after which she noted a significant deterioration in cognitive function, hypertension control, and diabetes. Over the past year, progression of all microand macrovascular complications of diabetes mellitus has been noted – nephropathy (decrease in SCF from 55 to 21 ml per min), retinopathy (non-proliferative retinopathy), significant deterioration of polyneuropathy, progression of atherosclerosis, confirmed by instrumental methods (ultrasound Doppler imaging of the lower extremities, ultrasound Doppler imaging of the cerebral vessels). The data are consistent with severe post-COVID syndrome. The results are compared with global data. Risk factors for the development of post-COVID syndrome are identified. Associations of single-nucleotide polymorphisms of pleotropic genes with the development of severe post-COVID syndrome are found. Personalized therapy is identified.

  • Open Access

    Genetic polymorphism of post-COVID syndrome in patients with type 2 diabetes mellitus

    by S. A. Sukhanov, O. V. Zanozina, Yu. A. Sorokina, V. N. Lagonskaya, M. V. Kobalava, С. А. Суханов, О. В. Занозина, Ю. А. Сорокина, В. Н. Лагонская, М. В. Кобалава

    The long-term consequences of COVID-19 remain poorly understood. All authors agree on one thing: single nucleotide polymorphisms (SNPs) have the potential to become a valuable tool for predicting long-term clinical outcome in patients infected with SARS-CoV-2. Thus, the ACE2 rs2106809 SNP has been shown to be a functional marker of brain changes, and its potential involvement in long-term COVID-19 requires further study. Recent studies have linked the FOXP4 gene to the severity of COVID-19 and the risk of long-term COVID-19. SNP rs9367106 is likely associated with the development of long-term symptomatic abnormalities in the lungs and brain observed after recovery from COVID-19. Olfactory and gustatory impairment has been identified as a pathognomonic feature not only of acute COVID-19 but also of post-COVID chronic fatigue syndrome, and is determined by the leading single nucleotide polymorphism rs10893121. Also, CC genotypes of the methylenetetrahydrofolate reductase (MTHFR) gene were statistically more common in chronic COVID-19. It can be assumed that some variants of nucleotide sequences involved in the genesis of diabetes and its complications, in the formation of patient comorbidity, and in the development of COVID, may potentially participate in the formation of PCS in patients with diabetes. We have demonstrated an association with post-COVID syndrome of single nucleotide polymorphisms in the following genes: FABP2, NOS3, COMT, and PAI-1. Subsequently, phenotypes of post-COVID syndrome will be developed in patients with type 2 diabetes, taking into account genetic determinants. A prognosis for the post-COVID period in this category of patients will be determined. Consequently, personalized treatment for patients will be developed, taking into account the combination of pathological alleles of pleiotropic genes.

  • Emerging evidence on post-COVID syndrome in patients with type 2 diabetes

    by S. A. Sukhanov, O. V. Zanozina, Yu. A. Sorokina, V. N. Lagonskaya, M. V. Kobalava

    The novel coronavirus pandemic that ravaged the world has passed, but challenges remain. The long-term consequences of COVID-19 are remain poorly understood. The term “post-COVID syndrome” currently has a temporal component, a clinical and laboratory component, some biomolecular markers have been identified, risk factors for the development of this complication after a coronavirus infection have been determined, and the genetic component of post-COVID syndrome is being clarified. However, regarding post-COVID syndrome in patients with type 2 diabetes, the data are conflicting. Data on the prevalence of post-COVID disorders vary widely, even within a single country. On average, in Europe, the frequency of PCOS in patients with type 2 diabetes is 66.8%, with the maximum frequency being at the age of 50 years. New biomarkers of post-COVID syndrome in patients with type 2 diabetes are emerging, and prognostic criteria for its development in this category of patients are being developed. It was shown that the telomere length was significantly shorter in patients with type 2 diabetes mellitus and post-COVID syndrome than in individuals without post-COVID disorders. High levels of podocyte-specific proteins and neutrophil elastase can serve as criteria for this syndrome. We assessed the significance of some leukocyte indices in the diagnosis and monitoring of the consequences of a new coronavirus infection in patients with type 2 diabetes. However, many unanswered questions remain, in particular, whether there is a genetic predisposition to the development of chronic COVID-19 in patients with diabetes. We previously conducted an analytical review of the presence of PCS in patients with type 2 diabetes. The purpose of this publication was to summarize new data in the literature on the main points outlined previously and to present our own results.

  • Significance of certain leukocyte indices in patients with type 2 diabetes who have had novel coronavirus infection

    by S. A. Sukhanov, Yu. A. Sorokina, O. V. Zanozina, A. A. Mosinа, I. D. Kapranova

    Сhronic low-intensity inflammation is the one of the mechanisms of development of diabetes mellitus type 2. In order to objectify this process, some leukocyte indices are used (the ratio of neutrophils to lymphocytes – NLR, the ratio of platelets to lymphocytes – PLR, the ratio of lymphocytes to monocytes – LMR, the ratio of monocytes to lymphocytes – MLR, as well as the index of systemic immune inflammation SII (calculated taking into account neutrophils, lymphocytes, platelets), taking into account the presence of both microvascular and macrovascular late complications in patients with diabetes mellitus. The new coronavirus infection significantly increases the inflammation process that’s why some leukocyte indices are to be prognostic markers of the disease outcomes. The article presents the latest data on the significance of inflammation markers in multimorbid patients with a new coronavirus infection. It is emphasized that data on the study of leukocyte indices in patients with diabetes mellitus who have had a new coronavirus infection are scarce, and information on the use of such a simple tool for studying inflammation as leukocyte indices in assessing post-COVID disorders in patients with diabetes mellitus is absent. Our data concluded that the learning information about inflammation in patients with type 2 diabetes and post-COVID syndrome using leukocyte indices is really promising.


  • Open Access

    A smart device for smart self-monitoring of glycemia in patients with diabetes

    by O. V. Zanozina, Yu. A. Sorokina, N. Yu. Taradayko, S. A. Sukhanov, T. S. Aksenova, Н. Ю. Тарадайко

    Systemic vascular complications of diabetes mellitus (nephropathy, retinopathy, injuries to the great vessels of the heart, brain, arteries of the lower extremities) have been proven to lead to early disability and premature death of patients. The annual economic costs of T2DM and associated cardiovascular complications account for at least 1% of GDP. According to the principles of therapeutic management of diabetes mellitus, patient education is viewed as an integrated component of the treatment process. It should provide patients with knowledge and skills that contribute to achieving specific therapeutic goals (disease self-management). Self-monitoring of blood glucose training is a priority objective in the treatment of patients with diabetes. It is self-monitoring of glycemia that is the most important criterion for selecting therapy, compared with the glycemia testing in an outpatient clinic or hospital settings. Modern glucometers provide an option for remote monitoring of glycemia and timely delivering of consultations using a mobile application. Thus, Contour Plus One glucometer with the Russian-language application Contour Diabitis records the blood glucose readings following each test. If low or high glycaemic levels are detected, the application will show a notification and offer the patient options for actions. Quick recognizing out-of-range lab results motivates patients and helps them understand why changes in therapy are required. Immediate notifications shown on the smartphone screen improve motivation to act and respond to the situation. The glucometer system with a mobile application allows to promptly manage glycemia, increase patient’s commitment to active disease management, achieve treatment goals using innovative technologies, and therefore actively manage the course of diabetes mellitus.


  • Open Access

    Post-COVID syndrome in patients with type 2 diabetes: definition, epidemiology, pathophysiology, biomarkers and genetic associations

    by S. A. Sukhanov, Yu. A. Sorokina, O. V. Zanozina

    The article presents the modern ideas about post-COVID syndrome, indicates various types and classifications of post-COVID syndrome, provides epidemiological data, including the patients with type 2 diabetes, also the definition of post-COVID syndrome is given. The group of patients defined as patients with post-COVID syndrome is very heterogeneous. Post-COVID syndrome is more common in the elderly, with comorbid pathology, severe disease. The pathophysiology of this syndrome in patients with type 2 diabetes mellitus is analyzed, and risk factors are indicated. The main biomarkers of disorders were determined: monocytes and their coefficients, acute phase proteins, some biochemical indicators, including analysis of genetic associations with the severity of post-COVID disorders (interferon gamma gene, methylenetetrahydrofolate reductase gene, ACE2 inhibitor). Genotyping of a sample of 26 single nucleotide polymorphisms in genes implicated in viral entry, immune response, and inflammation were significantly associated not only with the risk of long-term COVID-19 symptoms, but also with the cumulative incidence of post-COVID syndrome. Elevated levels of interleukin 6, C-reactive protein and tumor necrosis factor alpha may serve as potential diagnostic biomarkers in long-term COVID biomarkers of blood vascular transformation have great potential for diagnosis, and angiogenesis modulators may have therapeutic efficacy It has been shown that the vast majority of patients, in particular those suffering from type 2 diabetes, develop post-COVID-19 syndrome, and taking into account pre-existing diseases, post-COVID syndrome is not so harmless. By identifying common biomarkers and genetic associations, it is possible to identify the common molecular mechanism of post-COVID syndrome COVID-19 and diabetes mellitus. The novelty of disease association studies in the context of COVID-19 provides new insights into the management of rapidly evolving long-term COVID and post-COVID syndromes that have significant global implications.


  • Cognitive disorders in patients with hypertonic cerebral microangiopathy associated with type 2 diabetes mellitus and COVID-19

    by Semenova T.N. Semenova, Grigoryeva V.N. Grigoryeva, Zanozina O.V. Zanozina, Sukhanov S.A. Sukhanov, N.A. Semashko Nizhny Novgorod Regional Clinical Hospital

  • Open Access

    Cardiovascular pathology and intestinal microbiome relationship: potential targets of pharmacotherapy

    by Y. A. Sorokina, N. A. Petunina, S. D. Sinyushkina, A. V. Gorinova, M. I. Pryazhnikova, S. A. Sukhanov, A. S. Rudakov, O. V. Zanozina

    Связь сердечно-сосудистой патологии и микробиома кишечника: потенциальные мишени фармакотерапии